Elongated tissue matrices
View Patent ↗Elongated and high aspect ratio tissue treatment products are provided. Methods of making and using the tissue treatment products are also provided. The tissue treatment products can be used as implants that conform to the site of implantation and resist migration away from their implantation site in vivo.
1. A method for treating a surgical site in a breast after a lumpectomy procedure, comprising selecting a surgical site; removing native breast tissue; selecting an amount of a tissue treatment product sufficient to replace the native tissue excised from the surgical site; and implanting the tissue treatment product into the surgical site, wherein the tissue treatment product comprises:
a collection of loosely arranged elongated elements lacking an organized tertiary structure, each elongated element comprising a tissue matrix that has been at least partially decellularized, and
wherein each elongated element has a flexible three-dimensional structure comprising a length dimension, a width dimension, and a height dimension, and wherein one dimension is substantially larger than the other two dimensions, wherein the collection of loosely arranged elongated elements are implanted in contact with surrounding tissue to allow ingrowth of cells.
2. The method of claim 1 , wherein implanting the tissue treatment product preserves the look and feel of breast tissue prior to surgical removal of native tissue, while providing a structural scaffold in which native cells and vasculature can migrate and proliferate.
3. The method of claim 2 , wherein the implanted tissue treatment product promotes or enhances breast tissue repair, regeneration, or treatment by providing a scaffold for the regeneration of native breast tissue and by reducing the volume of fibrosis formed at the site of surgical intervention, as compared to fibrosis formation in the absence of an implanted tissue treatment product.
4. A method of treatment, comprising implanting a tissue treatment product into a tissue in need of repair, regeneration, healing, treatment, or alteration, wherein the tissue treatment product comprises:
a collection of loosely arranged elongated elements lacking an organized tertiary structure, each elongated element comprising a tissue matrix that has been at least partially decellularized, and
wherein each elongated element has a flexible three-dimensional structure comprising a length dimension, a width dimension, and a height dimension, and wherein one dimension is substantially larger than the other two dimensions, wherein the collection of loosely arranged elongated elements are implanted in contact with surrounding tissue to allow ingrowth of cells.
5. The method of claim 4 , wherein the tissue treatment product conforms to the anatomic shape of an implant site, resists migrating away from the implant site after implantation, and allows for the continued passage of fluid at the site of implantation.
6. The method of claim 5 , wherein the implanted tissue treatment product provides a structural scaffold in which native cells and vasculature can migrate and proliferate.
7. The method of claim 6 , wherein the tissue treatment product promotes or enhances tissue repair, regeneration, healing, treatment, or alteration.
8. The method of claim 4 , wherein the tissue treatment product is implanted for cosmetic purposes.
9. The method of claim 8 , wherein the tissue treatment product is used in combination with a breast implant.
10. The method of claim 4 , wherein the tissue treatment product is implanted following the removal of native tissue.
11. The method of claim 10 , wherein the tissue being removed is a tumor.
12. The method of claim 11 , wherein the tumor is a breast tumor.
13. The method of claim 10 , wherein implanting a tissue treatment product preserves the approximate look or feel of the native tissue after implantation, as compared to the look or feel in the absence of an implanted tissue treatment product.
14. The method of claim 4 , wherein the tissue treatment product is implanted following surgical separation of native tissues.
15. The method of claim 14 , wherein implanting the tissue treatment product leads to faster healing of the separated native tissues, as compared to healing in the absence of an implanted tissue treatment product.
16. The method of claim 4 , wherein the tissue treatment product is implanted in a wound or other void space that occurs through injury or disease.
17. The method of claim 16 , wherein implanting the tissue treatment product leads to faster healing of the wound or void space, as compared to healing in the absence of an implanted tissue treatment product.
18. The method of claim 4 , wherein the tissue treatment product comprises a collection of elements that have a high aspect ratio.
19. The method of claim 18 , wherein the high aspect ratio elements in the tissue treatment product have one dimension that is at least about five times as large as the other two dimensions.
20. The method of claim 18 , wherein the high aspect ratio elements in the tissue treatment product have one dimension that is at least about ten times as large as the other two dimensions.
21. The method of claim 18 , wherein the high aspect ratio elements in the tissue treatment product have one dimension that is at least about 100 times as large as the other two dimensions.
22. The method of claim 4 , wherein the tissue treatment product comprises a partially or fully decellularized tissue matrix from at least one of human, non-human primate, pig, cow, horse, goat, sheep, dog, cat, rabbit, guinea pig, gerbil, hamster, rat, and mouse tissue.
23. The method of claim 4 , wherein the tissue treatment product comprises the partially or fully decellularized tissue matrix from at least one of bone, skin, dermis, intestine, vascular, urinary bladder, tendon, ligament, muscle, fascia, neurologic tissue, vessel, liver, heart, lung, kidney, or cartilage tissue.
24. The method of claim 4 , wherein the tissue treatment product further comprises one or more viable and histocompatible cells.
25. The method of claim 4 , wherein the tissue treatment product further comprises at least one additional factor selected from an anti-inflammatory agent, an analgesic, a cell growth factor, an angiogenic factor, a differentiation factor, a cytokine, a hormone, and a chemokine.
26. The method of claim 4 , wherein the tissue treatment product substantially lacks all bioburden.
27. The method of claim 4 , wherein the tissue treatment product is injected through a syringe.